Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Total Valuation
NeoGenomics has a market cap or net worth of $1.33B. The enterprise value is $568.59M.
Market Cap$1.33B
Enterprise Value$568.59M
Share Statistics
NeoGenomics has 129,812,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,812,210
Owned by Insiders1.25%
Owned by Institutions6.82%
Financial Efficiency
NeoGenomics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -5.07%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-5.07%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee330.61K
Profits Per Employee-49.10K
Employee Count2,200
Asset Turnover0.53
Inventory Turnover15.57
Valuation Ratios
The current PE Ratio of NeoGenomics is ―. NeoGenomics’s PEG ratio is -0.08.
PE Ratio―
PS Ratio0.41
PB Ratio0.36
Price to Fair Value0.36
Price to FCF-13.83
Price to Operating Cash Flow48.66
PEG Ratio-0.08
Income Statement
In the last 12 months, NeoGenomics had revenue of 727.33M and earned -108.03M in profits. Earnings per share was -4.20.
Revenue727.33M
Gross Profit282.54M
Operating Income-66.08M
Pretax Income-110.27M
Net Income-108.03M
EBITDA1.75M
Earnings Per Share (EPS)-4.20
Cash Flow
In the last 12 months, operating cash flow was 5.23M and capital expenditures -27.01M, giving a free cash flow of -21.78M billion.
Operating Cash Flow5.23M
Free Cash Flow-21.78M
Free Cash Flow per Share-0.17
Dividends & Yields
NeoGenomics pays an annual dividend of $0.4, resulting in a dividend yield of ―
Dividend Per Share$0.4
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.12
52-Week Price Change-11.46%
50-Day Moving Average12.04
200-Day Moving Average9.18
Relative Strength Index (RSI)26.50
Average Volume (3m)1.98M
Important Dates
NeoGenomics upcoming earnings date is May 5, 2026, TBA (Confirmed).
Last Earnings DateFeb 17, 2026
Next Earnings DateMay 5, 2026
Ex-Dividend Date―
Financial Position
NeoGenomics as a current ratio of 4.26, with Debt / Equity ratio of 56.45%
Current Ratio4.26
Quick Ratio3.94
Debt to Market Cap1.36
Net Debt to EBITDA179.17
Interest Coverage Ratio-17.61
Taxes
In the past 12 months, NeoGenomics has paid -2.24M in taxes.
Income Tax-2.24M
Effective Tax Rate0.02
Enterprise Valuation
NeoGenomics EV to EBITDA ratio is 351.84, with an EV/FCF ratio of -28.19.
EV to Sales0.84
EV to EBITDA351.84
EV to Free Cash Flow-28.19
EV to Operating Cash Flow117.39
Balance Sheet
NeoGenomics has $159.62M in cash and marketable securities with $472.28M in debt, giving a net cash position of -$312.66M billion.
Cash & Marketable Securities$159.62M
Total Debt$472.28M
Net Cash-$312.66M
Net Cash Per Share-$2.41
Tangible Book Value Per Share$1.00
Margins
Gross margin is 42.16%, with operating margin of -9.09%, and net profit margin of -14.85%.
Gross Margin42.16%
Operating Margin-9.09%
Pretax Margin-15.16%
Net Profit Margin-14.85%
EBITDA Margin0.24%
EBIT Margin-9.09%
Analyst Forecast
The average price target for NeoGenomics is $14.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.75
Price Target Upside49.14% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast10.10%
EPS Growth Forecast-44.29%